Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen

被引:44
作者
Bord, S
Frith, E
Ireland, DC
Scott, MA
Craig, JIO
Compston, JE
机构
[1] Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Haematol, Cambridge CB2 2QQ, England
[2] Univ Cambridge, Sch Clin Med, Cambridge, England
关键词
megakaryocytopoiesis; immunocytochemistry; bone remodelling; oestradiol;
D O I
10.1111/j.1365-2141.2004.05024.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To investigate the mechanisms by which megakaryocytes (MKs) may influence bone remodelling, CD34(+) cells were cultured for 6, 9 and 12 d with or without 17beta-oestradiol (E) and immunolocalized for osteoprotegerin (OPG), receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) and CD61. Specific protein expression was measured quantitatively by image analysis. Fluorescence-based immunocytochemistry was used to co-localize OPG and RANKL with CD61. OPG and RANKL mRNA was assessed in CD61(+) cells with or without E at 24 and 48 h. At 6 d, OPG and RANKL expression was unchanged by E treatment. At 9 d, the E-treated cultures with maturing MKs showed a 1.72-fold (P < 0.01) increase in OPG expression and a 1.8-fold (P < 0.01) reduction in RANKL. Maximal OPG expression was seen at 12 d with a threefold induction of expression (P < 0.001), whilst RANKL levels were further suppressed by 2.3-fold compared with controls (P < 0.001). CD61 co-localized with OPG and RANKL. mRNA data were consistent with that of protein, with a 90-fold induction in OPG expression and a 34-fold suppression of RANKL expression by E (P < 0.001). Thus, E stimulates megakaryocytopoiesis and modulates OPG and RANKL expression, providing evidence that MKs may play a role in bone remodelling and, in particular, in E-induced changes in osteoclastogenesis and bone resorption.
引用
收藏
页码:244 / 251
页数:8
相关论文
共 40 条
[31]  
SAMUELS A, 1998, J BONE MINER RES, V13, pO16
[32]   Osteoprotegerin: A novel secreted protein involved in the regulation of bone density [J].
Simonet, WS ;
Lacey, DL ;
Dunstan, CR ;
Kelley, M ;
Chang, MS ;
Luthy, R ;
Nguyen, HQ ;
Wooden, S ;
Bennett, L ;
Boone, T ;
Shimamoto, G ;
DeRose, M ;
Elliott, R ;
Colombero, A ;
Tan, HL ;
Trail, G ;
Sullivan, J ;
Davy, E ;
Bucay, N ;
RenshawGegg, L ;
Hughes, TM ;
Hill, D ;
Pattison, W ;
Campbell, P ;
Sander, S ;
Van, G ;
Tarpley, J ;
Derby, P ;
Lee, R ;
Boyle, WJ .
CELL, 1997, 89 (02) :309-319
[33]   THE ESTROGEN-RECEPTOR IS PRESENT IN HUMAN MEGAKARYOCYTES [J].
TARANTINO, MD ;
KUNICKI, TJ ;
NUGENT, DJ .
PLATELET-DEPENDENT VASCULAR OCCLUSION, 1994, 714 :293-296
[34]   PRESENCE OF MESSENGER-RIBONUCLEIC-ACID ENCODING OSTEOCALCIN, A MARKER OF BONE TURNOVER, IN BONE-MARROW MEGAKARYOCYTES AND PERIPHERAL-BLOOD PLATELETS [J].
THIEDE, MA ;
SMOCK, SL ;
PETERSEN, DN ;
GRASSER, WA ;
THOMPSON, DD ;
NISHIMOTO, SK .
ENDOCRINOLOGY, 1994, 135 (03) :929-937
[35]  
TSAI MJ, 1998, TXB ENDOCRINOLOGY, P55
[36]   Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis [J].
Tsuda, E ;
Goto, M ;
Mochizuki, S ;
Yano, K ;
Kobayashi, F ;
Morinaga, T ;
Higashio, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 234 (01) :137-142
[37]   SKELETAL EFFECTS OF ESTROGEN [J].
TURNER, RT ;
RIGGS, BL ;
SPELSBERG, TC .
ENDOCRINE REVIEWS, 1994, 15 (03) :275-300
[38]   The effects of long-term hormone replacement therapy on bone remodeling in postmenopausal women [J].
Vedi, S ;
Compston, JE .
BONE, 1996, 19 (05) :535-539
[39]   Bone remodeling and structure in postmenopausal women treated with long-term, high-dose estrogen therapy [J].
Vedi, S ;
Purdie, DW ;
Ballard, P ;
Bord, S ;
Cooper, AC ;
Compston, JE .
OSTEOPOROSIS INTERNATIONAL, 1999, 10 (01) :52-58
[40]   The effect of long term oestradiol implantation on bone mineral density in postmenopausal women who have undergone hysterectomy and bilateral oophorectomy [J].
Wahab, M ;
Ballard, P ;
Purdie, DW ;
Cooper, A ;
Willson, JC .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1997, 104 (06) :728-731